Patient-Derived Xenograft / PDX Model Market by Type (Mice, Rat), Implantation Method (Subcutaneous, Orthotopic), Tumor Type (Respiratory, Hematological), Application (Drug Development, Biobanks), End User (Pharma, Biotech, CROs) - Global Forecast to 2028
The patient-derived xenografts/ PDX model market is projected to reach USD 687 million by 2028 from USD 366 million in 2023, at a CAGR of 13.4% during the forecast period. The key factors driving the growth of the global patient-derived xenograft/ PDX model market are the enhanced preclinical predictability, advancement of personalized medicine, and rise in the prevalence of cancer. However, ethical concerns surrounding the use of animal models are expected to restrain market growth to a certain extent.
The patient-derived xenografts/ PDX models market has been segmented based on type, implantation method, tumor type, application, end-user, and region.
“By type, the mouse model segment accounted for the largest share of the patient-derived xenografts/ PDX models market.”
Based on type, the patient-derived xenografts/ PDX models market is categorized into mouse model and rat model. The mouse model segment is the largest and fastest-growing segment in the market in 2023, owing to ease of manipulation and procurement, and the minimum requirement for keeping them under observation compared to rats in the facilities has led to a higher growth rate for products in the patient-derived xenografts/ PDX models market.
“By implantation method, subcutaneous implantation segment accounted for the largest share in the patient-derived xenografts/ PDX models market.”
Based on implantation method, the market is segmented into subcutaneous implantation, orthotopic implantation, and other implantation methods (heterotopic implantation, intraocular implantation, and under the renal capsule). In 2023, the subcutaneous segment accounted for the largest share and the fastest-growing segment of the patient-derived xenografts/ PDX models market. Subcutaneous implantation involves implanting patient-derived tumor tissue under the skin of a host animal (often a mouse). This method is relatively simple and minimally invasive compared to other implantation methods, making it a practical choice for researchers.
“North America: the largest share of the patient-derived xenografts/ PDX models market.”
North America accounted for the largest share of the patient-derived xenografts/ PDX models market. The region possesses a highly developed and robust biopharmaceutical industry, with advanced research and clinical infrastructure. This environment facilitates efficient collaboration between academia, research institutions, and pharmaceutical companies, enabling the effective utilization and adoption of PDX models.
Secondly, North America's regulatory framework supports the integration of innovative technologies, including PDX models, in preclinical and clinical research. The stringent regulatory standards ensure that PDX models are validated and applicable for drug development processes, thereby bolstering investor and industry confidence.
Moreover, the APAC region offers lucrative growth potential for the PDX models market. This region benefits from a robust healthcare infrastructure, a burgeoning biopharmaceutical industry, and a large patient population, fostering an ideal setting for PDX model utilization.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the patient-derived xenografts/ PDX models market. It aims at estimating the size and future growth potential of the market across different segments, such as type, implantation method, tumor type, application, and end-user, and region (North America, Europe, Asia Pacific, Latin America, and Middle East Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall patient-derived xenografts/ PDX models market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provides insights on the following pointers:
The patient-derived xenografts/ PDX models market has been segmented based on type, implantation method, tumor type, application, end-user, and region.
“By type, the mouse model segment accounted for the largest share of the patient-derived xenografts/ PDX models market.”
Based on type, the patient-derived xenografts/ PDX models market is categorized into mouse model and rat model. The mouse model segment is the largest and fastest-growing segment in the market in 2023, owing to ease of manipulation and procurement, and the minimum requirement for keeping them under observation compared to rats in the facilities has led to a higher growth rate for products in the patient-derived xenografts/ PDX models market.
“By implantation method, subcutaneous implantation segment accounted for the largest share in the patient-derived xenografts/ PDX models market.”
Based on implantation method, the market is segmented into subcutaneous implantation, orthotopic implantation, and other implantation methods (heterotopic implantation, intraocular implantation, and under the renal capsule). In 2023, the subcutaneous segment accounted for the largest share and the fastest-growing segment of the patient-derived xenografts/ PDX models market. Subcutaneous implantation involves implanting patient-derived tumor tissue under the skin of a host animal (often a mouse). This method is relatively simple and minimally invasive compared to other implantation methods, making it a practical choice for researchers.
“North America: the largest share of the patient-derived xenografts/ PDX models market.”
North America accounted for the largest share of the patient-derived xenografts/ PDX models market. The region possesses a highly developed and robust biopharmaceutical industry, with advanced research and clinical infrastructure. This environment facilitates efficient collaboration between academia, research institutions, and pharmaceutical companies, enabling the effective utilization and adoption of PDX models.
Secondly, North America's regulatory framework supports the integration of innovative technologies, including PDX models, in preclinical and clinical research. The stringent regulatory standards ensure that PDX models are validated and applicable for drug development processes, thereby bolstering investor and industry confidence.
Moreover, the APAC region offers lucrative growth potential for the PDX models market. This region benefits from a robust healthcare infrastructure, a burgeoning biopharmaceutical industry, and a large patient population, fostering an ideal setting for PDX model utilization.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 63% and Demand Side- 37%
- By Designation: Executives - 45%, Research Scientists- 30%, and Managers - 25%
- By Country: North America- 40%, Europe- 25%, Asia Pacific- 20%, Latin America - 10%, and Middle East Africa- 5%
- JSR Corporation (Japan)
- Wuxi Apptec (China)
- The Jackson Laboratory (US)
- Charles River Laboratories International, Inc. (US)
- Taconic Biosciences, Inc. (US)
- Oncodesign Precision Medicine (France)
- Inotiv, Inc. (US)
- Pharmatest Services (Finland)
- Hera BioLabs (US)
- EPO Berlin-Buch GmbH (Germany)
- Xentech (France)
- Urosphere (France)
- Altogen Labs (US)
- Abnova Corporation (US)
- Genesis Biotechnology Group (US)
- Biocytogen Pharmaceuticals Co., Ltd. (China)
- Creative Animodel (US)
- BioDuro-Sundia (US)
- Aragen Life Sciences (India)
- Shanghai LIDE Biotech Co., Ltd. (China)
- Certis Oncology Solutions (US)
- InnoSer (Netherlands)
- IVRS AB (Sweden)
- Beijing IDMO Co. Ltd. (China)
- Shanghai Chempartner Co. Ltd. (China)
This report provides a detailed picture of the patient-derived xenografts/ PDX models market. It aims at estimating the size and future growth potential of the market across different segments, such as type, implantation method, tumor type, application, and end-user, and region (North America, Europe, Asia Pacific, Latin America, and Middle East Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall patient-derived xenografts/ PDX models market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (growing demand for personalized medicine, technological advancements in PDX technology, and rising investments for cancer research), restraints (FDA’s announcement to discontinue animal models for clinical trials), opportunities (emergence of CRISPR in biomedical research), and challenges (development of alternative animal testing methods) influencing the growth of the patient-derived xenografts/ PDX models market.
- Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the patient-derived xenografts/ PDX models market.
- Market Development: Comprehensive information about lucrative markets- the report analyses the patient-derived xenografts/ PDX models market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the patient-derived xenografts/ PDX models market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like JSR Corporation (Japan), The Jackson Laboratory (US), and Charles River Laboratories International, Inc. (US), among others, in the patient-derived xenografts/ PDX models market strategies. The report also helps stakeholders understand the pulse of the patient-derived xenografts/ PDX models market and provides them with information on key market drivers, restraints, challenges, and opportunities.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS AND EXCLUSIONS
1.4 STUDY SCOPE
1.4.1 MARKETS COVERED
1.4.2 YEARS CONSIDERED
1.4.3 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.8 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2023
FIGURE 4 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET SIZE, 2023 (USD MILLION)
FIGURE 5 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: FINAL CAGR PROJECTIONS, 2023?2028
FIGURE 6 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.3 DATA TRIANGULATION METHODOLOGY
FIGURE 7 DATA TRIANGULATION
2.4 INDUSTRY INSIGHTS
2.5 RESEARCH ASSUMPTIONS
2.6 RECESSION IMPACT
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (%)
TABLE 2 US HEALTHCARE EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 3 US HEALTHCARE EXPENDITURE, 2023–2027 (USD MILLION)
3 EXECUTIVE SUMMARY
FIGURE 8 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 9 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2023 VS. 2028 (USD MILLION)
FIGURE 10 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 11 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION
4 PREMIUM INSIGHTS
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET
FIGURE 12 RISING INVESTMENTS IN CANCER RESEARCH AND ADVANCEMENTS IN PDX TECHNOLOGY
4.2 NORTH AMERICAN PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER AND COUNTRY (2023)
FIGURE 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT AND US TO ACCOUNT FOR LARGEST SHARES OF NORTH AMERICAN PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET IN 2023
4.3 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION
FIGURE 14 PRECLINICAL DRUG DEVELOPMENT SEGMENT TO HOLD LARGEST MARKET SHARE IN 2028
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 4 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Growing demand for personalized medicine
5.2.1.2 Technological advancements in patient-derived xenograft (PDX) models
5.2.1.3 Rising investments in cancer research
5.2.2 RESTRAINTS
5.2.2.1 Discontinuation of animal models for clinical trials by FDA
5.2.3 OPPORTUNITIES
5.2.3.1 Emergence of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) in biomedical research
5.2.4 CHALLENGES
5.2.4.1 Development of alternative animal testing methods
5.3 TECHNOLOGY ANALYSIS
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 16 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET
5.5 SUPPLY CHAIN ANALYSIS
FIGURE 17 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: SUPPLY CHAIN ANALYSIS
TABLE 5 COMPANIES AND THEIR ROLE IN PATIENT-DERIVED XENOGRAFT (PDX) MODEL SUPPLY CHAIN
5.6 VALUE CHAIN ANALYSIS
FIGURE 18 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
FIGURE 19 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: ECOSYSTEM ANALYSIS
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 6 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 INTENSITY OF COMPETITIVE RIVALRY
5.8.2 BARGAINING POWER OF SUPPLIERS
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 THREAT OF SUBSTITUTES
5.8.5 THREAT OF NEW ENTRANTS
5.9 REGULATORY ANALYSIS
5.9.1 NORTH AMERICA
5.9.2 EUROPE
5.9.3 ASIA PACIFIC
5.9.3.1 China
5.9.3.2 Japan
5.9.3.3 India
5.9.3.4 Australia
5.9.4 LATIN AMERICA
5.9.5 MIDDLE EAST & AFRICA
5.10 PRICING ANALYSIS
5.10.1 AVERAGE SELLING PRICE (ASP) OF PRODUCTS OFFERED BY THREE KEY PLAYERS, BY TYPE
TABLE 7 AVERAGE SELLING PRICE (ASP) OF PRODUCTS OFFERED BY THREE KEY PLAYERS, BY TYPE (USD)
5.10.2 AVERAGE SELLING PRICE (ASP) TREND
5.11 PATENT ANALYSIS
FIGURE 20 GRANTED PATENTS FOR PDX MODELS, 2011–2023
5.12 KEY CONFERENCES AND EVENTS IN 2023
TABLE 8 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: KEY CONFERENCES AND EVENTS
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
5.13.2 BUYING CRITERIA
FIGURE 22 KEY BUYING CRITERIA FOR THREE KEY END USERS
6 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD
6.1 INTRODUCTION
TABLE 9 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
6.2 SUBCUTANEOUS IMPLANTATION
6.2.1 FACILITATES REAL-TIME ASSESSMENT OF TUMOR GROWTH
TABLE 10 SUBCUTANEOUS IMPLANTATION: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 11 SUBCUTANEOUS IMPLANTATION: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 12 SUBCUTANEOUS IMPLANTATION: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 13 SUBCUTANEOUS IMPLANTATION: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 14 SUBCUTANEOUS IMPLANTATION: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 15 SUBCUTANEOUS IMPLANTATION: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 ORTHOTOPIC IMPLANTATION
6.3.1 PROVIDES HIGHLY ACCURATE REPRESENTATION OF TUMOR BEHAVIOR
TABLE 16 ORTHOTOPIC IMPLANTATION: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 17 ORTHOTOPIC IMPLANTATION: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 18 ORTHOTOPIC IMPLANTATION: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 19 ORTHOTOPIC IMPLANTATION: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 20 ORTHOTOPIC IMPLANTATION: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 21 ORTHOTOPIC IMPLANTATION: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.4 OTHERS
TABLE 22 OTHERS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 23 OTHERS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 24 OTHERS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 25 OTHERS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 26 OTHERS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 27 OTHERS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE
7.1 INTRODUCTION
TABLE 28 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
7.2 MOUSE MODEL
7.2.1 GROWING USE IN CANCER RESEARCH AND DRUG DEVELOPMENT
TABLE 29 MOUSE MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 30 MOUSE MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 31 MOUSE MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 32 MOUSE MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 33 MOUSE MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 34 MOUSE MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 RAT MODEL
7.3.1 DEVELOPMENT OF NEW TECHNOLOGIES TO CREATE PDX RAT MODELS AT FASTER RATE
TABLE 35 RAT MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 36 RAT MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 37 RAT MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 38 RAT MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 39 RAT MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 40 RAT MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 41 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
8.2 PRECLINICAL DRUG DEVELOPMENT
8.2.1 INCREASED NUMBER OF CLINICAL TRIALS
TABLE 42 PRECLINICAL DRUG DEVELOPMENT: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 43 PRECLINICAL DRUG DEVELOPMENT: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 44 PRECLINICAL DRUG DEVELOPMENT: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 45 PRECLINICAL DRUG DEVELOPMENT: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 46 PRECLINICAL DRUG DEVELOPMENT: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 47 PRECLINICAL DRUG DEVELOPMENT: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 BIOMARKER ANALYSIS
8.3.1 GROWING DEMAND FOR BIOMARKER-BASED PERSONALIZED CANCER THERAPY
TABLE 48 BIOMARKER ANALYSIS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 49 BIOMARKER ANALYSIS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 50 BIOMARKER ANALYSIS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 51 BIOMARKER ANALYSIS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 52 BIOMARKER ANALYSIS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 53 BIOMARKER ANALYSIS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8.4 TRANSLATIONAL RESEARCH
8.4.1 BOOMING PERSONALIZED MEDICINE MARKET
TABLE 54 TRANSLATIONAL RESEARCH: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 55 TRANSLATIONAL RESEARCH: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 56 TRANSLATIONAL RESEARCH: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 57 TRANSLATIONAL RESEARCH: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 58 TRANSLATIONAL RESEARCH: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 59 TRANSLATIONAL RESEARCH: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8.5 BIOBANKS
8.5.1 RISING DRUG DISCOVERY AND DEVELOPMENT PROJECTS
TABLE 60 BIOBANKS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 61 BIOBANKS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 62 BIOBANKS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 63 BIOBANKS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 64 BIOBANKS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 65 BIOBANKS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
9 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER
9.1 INTRODUCTION
TABLE 66 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 ADVANCEMENTS IN TUMOR MICROENVIRONMENT RESEARCH
TABLE 67 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 68 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 69 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, 2021–2028 (USD MILLION)
TABLE 70 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 71 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 72 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
9.3 CONTRACT RESEARCH ORGANIZATIONS (CROS)
9.3.1 INCREASING OUTSOURCING OF DRUG DISCOVERY SERVICES
TABLE 73 CONTRACT RESEARCH ORGANIZATIONS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 74 CONTRACT RESEARCH ORGANIZATIONS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 75 CONTRACT RESEARCH ORGANIZATIONS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 76 CONTRACT RESEARCH ORGANIZATIONS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 77 CONTRACT RESEARCH ORGANIZATIONS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 78 CONTRACT RESEARCH ORGANIZATIONS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
9.4 ACADEMIC & RESEARCH INSTITUTIONS
9.4.1 RISING R&D INVESTMENTS IN LIFE SCIENCES
TABLE 79 ACADEMIC & RESEARCH INSTITUTIONS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 80 ACADEMIC & RESEARCH INSTITUTIONS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 81 ACADEMIC & RESEARCH INSTITUTIONS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 82 ACADEMIC & RESEARCH INSTITUTIONS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 83 ACADEMIC & RESEARCH INSTITUTIONS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 84 ACADEMIC & RESEARCH INSTITUTIONS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE
10.1 INTRODUCTION
TABLE 85 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
10.2 GASTROINTESTINAL TUMOR MODEL
10.2.1 RISING DEMAND FOR EFFECTIVE CANCER THERAPEUTICS
TABLE 86 GASTROINTESTINAL TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 87 GASTROINTESTINAL TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 88 GASTROINTESTINAL TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 89 GASTROINTESTINAL TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 90 GASTROINTESTINAL TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 91 GASTROINTESTINAL TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.3 GYNECOLOGICAL TUMOR MODEL
10.3.1 HIGH INCIDENCE OF TARGET CANCERS
TABLE 92 GYNECOLOGICAL TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 93 GYNECOLOGICAL TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 94 GYNECOLOGICAL TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 95 GYNECOLOGICAL TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 96 GYNECOLOGICAL TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 97 GYNECOLOGICAL TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.4 RESPIRATORY TUMOR MODEL
10.4.1 INCREASING PREVALENCE OF LUNG CANCER
TABLE 98 RESPIRATORY TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 99 RESPIRATORY TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 100 RESPIRATORY TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 101 RESPIRATORY TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 102 RESPIRATORY TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 103 RESPIRATORY TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.5 UROLOGICAL TUMOR MODEL
10.5.1 INCREASING FOCUS OF COMPANIES ON EXPANDING PORTFOLIO OF UROLOGICAL TUMOR MODELS
TABLE 104 UROLOGICAL TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 105 UROLOGICAL TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 106 UROLOGICAL TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 107 UROLOGICAL TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 108 UROLOGICAL TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 109 UROLOGICAL TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.6 HEMATOLOGICAL TUMOR MODEL
10.6.1 ADVANCEMENTS IN TRANSLATIONAL RESEARCH AND INCREASING DEMAND FOR PERSONALIZED MEDICINE
TABLE 110 HEMATOLOGICAL TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 111 HEMATOLOGICAL TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 112 HEMATOLOGICAL TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 113 HEMATOLOGICAL TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 114 HEMATOLOGICAL TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 115 HEMATOLOGICAL TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.7 OTHERS
TABLE 116 OTHERS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 117 OTHERS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 118 OTHERS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 119 OTHERS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 120 OTHERS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 121 OTHERS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
11 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION
11.1 INTRODUCTION
TABLE 122 PATIENT-DERIVED XENOGRAFT MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 23 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET SNAPSHOT
TABLE 123 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 124 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 125 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 126 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 127 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 128 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.1 US
11.2.1.1 Growing federal research and development efforts to drive market
TABLE 129 US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 130 US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 131 US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 132 US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 133 US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Government-led investments in stem cell research to drive market
TABLE 134 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 135 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 136 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 137 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 138 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.3 NORTH AMERICA: IMPACT OF RECESSION
11.3 EUROPE
TABLE 139 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 140 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 141 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 142 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 143 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 144 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Increasing investments in biotechnology industry to boost market growth
TABLE 145 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 146 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 147 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 148 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 149 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.2 FRANCE
11.3.2.1 Increasing government funding for cancer research to support market growth
TABLE 150 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 151 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 152 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 153 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 154 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.3 UK
11.3.3.1 Rising focus on innovating oncology therapeutics to drive market
TABLE 155 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 156 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 157 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 158 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 159 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Growing biotechnology and pharmaceutical industries to drive market
TABLE 160 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 161 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 162 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 163 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 164 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Increasing investments in clinical trials to promote market growth
TABLE 165 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 166 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 167 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 168 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 169 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.6 REST OF EUROPE
TABLE 170 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 171 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 172 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 173 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 174 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.7 EUROPE: IMPACT OF RECESSION
11.4 ASIA PACIFIC
FIGURE 24 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET SNAPSHOT
TABLE 175 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 176 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 177 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 178 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 179 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 180 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.1 CHINA
11.4.1.1 Government-led fundings for clinical trials in oncology to drive market
TABLE 181 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 182 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 183 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 184 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 185 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Advancements in mice model technologies to drive market
TABLE 186 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 187 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 188 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 189 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 190 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Favorable government policies for drug development to fuel demand
TABLE 191 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 192 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 193 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 194 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 195 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.4 SOUTH KOREA
11.4.4.1 Rising investments in preclinical drug development to drive demand
TABLE 196 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 197 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 198 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 199 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 200 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.5 AUSTRALIA
11.4.5.1 Increased funding in clinical trials from research institutions to drive market
TABLE 201 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 202 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 203 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 204 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 205 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.6 REST OF ASIA PACIFIC
TABLE 206 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 207 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 208 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 209 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 210 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.7 ASIA PACIFIC: IMPACT OF RECESSION
11.5 LATIN AMERICA
TABLE 211 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 212 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 213 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 214 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 215 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 216 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.1 BRAZIL
11.5.1.1 Growing need for advanced cancer research and therapeutic development to drive market
TABLE 217 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 218 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 219 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 220 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 221 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.2 REST OF LATIN AMERICA
TABLE 222 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 223 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 224 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 225 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 226 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.3 LATIN AMERICA: IMPACT OF RECESSION
11.6 MIDDLE EAST & AFRICA
TABLE 227 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 228 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 229 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 230 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 231 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 232 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.6.1 MIDDLE EAST
11.6.1.1 Growing use to probe treatment strategies aligned with individual patient profiles to drive market
TABLE 233 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 234 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 235 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 236 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 237 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.6.2 AFRICA
11.6.2.1 Rising incidence of cancer and expanding research infrastructure to drive market
TABLE 238 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 239 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 240 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 241 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 242 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.6.3 MIDDLE EAST & AFRICA: IMPACT OF RECESSION
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS
FIGURE 25 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: KEY STRATEGIES ADOPTED BY MAJOR PLAYERS
12.3 REVENUE SHARE ANALYSIS OF TOP FOUR PLAYERS, 2022
FIGURE 26 REVENUE SHARE ANALYSIS FOR TOP FOUR COMPANIES, 2022
12.4 MARKET SHARE ANALYSIS OF TOP FOUR PLAYERS, 2020–2022
FIGURE 27 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET SHARE ANALYSIS OF TOP FOUR PLAYERS, 2020–2022
12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 28 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
12.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMALL AND MEDIUM-SIZED ENTERPRISES (SMES), 2022
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
FIGURE 29 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022
12.7 COMPETITIVE BENCHMARKING
12.7.1 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: LIST OF STARTUPS/SMES
TABLE 243 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: LIST OF STARTUPS/SMES
12.7.2 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
TABLE 244 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
12.8 COMPETITIVE SCENARIOS AND TRENDS
12.8.1 DEALS
TABLE 245 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: DEALS, 2021–2023
12.8.2 OTHERS
TABLE 246 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: OTHERS, 2021–2023
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 JSR CORPORATION
TABLE 247 JSR CORPORATION: COMPANY OVERVIEW
FIGURE 30 JSR CORPORATION: COMPANY SNAPSHOT
13.1.2 WUXI APPTEC
TABLE 248 WUXI APPTEC: COMPANY OVERVIEW
FIGURE 31 WUXI APPTEC: COMPANY SNAPSHOT
13.1.3 THE JACKSON LABORATORY
TABLE 249 THE JACKSON LABORATORY: COMPANY OVERVIEW
FIGURE 32 THE JACKSON LABORATORY: COMPANY SNAPSHOT
13.1.4 CHARLES RIVER LABORATORIES
TABLE 250 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
FIGURE 33 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
13.1.5 TACONIC BIOSCIENCES, INC.
TABLE 251 TACONIC BIOSCIENCES, INC.: COMPANY OVERVIEW
13.1.6 ONCODESIGN PRECISION MEDICINE
TABLE 252 ONCODESIGN PRECISION MEDICINE: COMPANY OVERVIEW
FIGURE 34 ONCODESIGN PRECISION MEDICINE: COMPANY SNAPSHOT
13.1.7 INOTIV, INC.
TABLE 253 INOTIV, INC.: COMPANY OVERVIEW
FIGURE 35 INOTIV, INC.: COMPANY SNAPSHOT
13.1.8 PHARMATEST SERVICES
TABLE 254 PHARMATEST SERVICES: COMPANY OVERVIEW
13.1.9 HERA BIOLABS
TABLE 255 HERA BIOLABS: COMPANY OVERVIEW
13.1.10 EPO BERLIN-BUCH GMBH
TABLE 256 EPO BERLIN-BUCH GMBH: COMPANY OVERVIEW
13.1.11 XENTECH
TABLE 257 XENTECH: COMPANY OVERVIEW
13.1.12 UROSPHERE
TABLE 258 UROSPHERE: COMPANY OVERVIEW
13.1.13 ALTOGEN LABS
TABLE 259 ALTOGEN LABS: COMPANY OVERVIEW
13.1.14 ABNOVA CORPORATION
TABLE 260 ABNOVA CORPORATION: COMPANY OVERVIEW
13.1.15 GENESIS BIOTECHNOLOGY GROUP
TABLE 261 GENESIS BIOTECHNOLOGY GROUP: COMPANY OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS
13.2.1 BIOCYTOGEN PHARMACEUTICALS CO., LTD.
13.2.2 CREATIVE ANIMODEL
13.2.3 BIODURO-SUNDIA INC.
13.2.4 ARAGEN LIFE SCIENCES
13.2.5 SHANGHAI LIDE BIOTECH CO., LTD.
13.2.6 CERTIS ONCOLOGY SOLUTIONS
13.2.7 INNOSER
13.2.8 IVRS AB
13.2.9 BEIJING IDMO CO. LTD.
13.2.10 SHANGHAI CHEM PARTNER CO. LTD.
14 APPENDIX
14.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.2 CUSTOMIZATION OPTIONS
14.3 RELATED REPORTS
14.4 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS AND EXCLUSIONS
1.4 STUDY SCOPE
1.4.1 MARKETS COVERED
1.4.2 YEARS CONSIDERED
1.4.3 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.8 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2023
FIGURE 4 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET SIZE, 2023 (USD MILLION)
FIGURE 5 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: FINAL CAGR PROJECTIONS, 2023?2028
FIGURE 6 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.3 DATA TRIANGULATION METHODOLOGY
FIGURE 7 DATA TRIANGULATION
2.4 INDUSTRY INSIGHTS
2.5 RESEARCH ASSUMPTIONS
2.6 RECESSION IMPACT
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (%)
TABLE 2 US HEALTHCARE EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 3 US HEALTHCARE EXPENDITURE, 2023–2027 (USD MILLION)
3 EXECUTIVE SUMMARY
FIGURE 8 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 9 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2023 VS. 2028 (USD MILLION)
FIGURE 10 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 11 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION
4 PREMIUM INSIGHTS
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET
FIGURE 12 RISING INVESTMENTS IN CANCER RESEARCH AND ADVANCEMENTS IN PDX TECHNOLOGY
4.2 NORTH AMERICAN PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER AND COUNTRY (2023)
FIGURE 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT AND US TO ACCOUNT FOR LARGEST SHARES OF NORTH AMERICAN PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET IN 2023
4.3 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION
FIGURE 14 PRECLINICAL DRUG DEVELOPMENT SEGMENT TO HOLD LARGEST MARKET SHARE IN 2028
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 4 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Growing demand for personalized medicine
5.2.1.2 Technological advancements in patient-derived xenograft (PDX) models
5.2.1.3 Rising investments in cancer research
5.2.2 RESTRAINTS
5.2.2.1 Discontinuation of animal models for clinical trials by FDA
5.2.3 OPPORTUNITIES
5.2.3.1 Emergence of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) in biomedical research
5.2.4 CHALLENGES
5.2.4.1 Development of alternative animal testing methods
5.3 TECHNOLOGY ANALYSIS
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 16 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET
5.5 SUPPLY CHAIN ANALYSIS
FIGURE 17 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: SUPPLY CHAIN ANALYSIS
TABLE 5 COMPANIES AND THEIR ROLE IN PATIENT-DERIVED XENOGRAFT (PDX) MODEL SUPPLY CHAIN
5.6 VALUE CHAIN ANALYSIS
FIGURE 18 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
FIGURE 19 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: ECOSYSTEM ANALYSIS
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 6 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 INTENSITY OF COMPETITIVE RIVALRY
5.8.2 BARGAINING POWER OF SUPPLIERS
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 THREAT OF SUBSTITUTES
5.8.5 THREAT OF NEW ENTRANTS
5.9 REGULATORY ANALYSIS
5.9.1 NORTH AMERICA
5.9.2 EUROPE
5.9.3 ASIA PACIFIC
5.9.3.1 China
5.9.3.2 Japan
5.9.3.3 India
5.9.3.4 Australia
5.9.4 LATIN AMERICA
5.9.5 MIDDLE EAST & AFRICA
5.10 PRICING ANALYSIS
5.10.1 AVERAGE SELLING PRICE (ASP) OF PRODUCTS OFFERED BY THREE KEY PLAYERS, BY TYPE
TABLE 7 AVERAGE SELLING PRICE (ASP) OF PRODUCTS OFFERED BY THREE KEY PLAYERS, BY TYPE (USD)
5.10.2 AVERAGE SELLING PRICE (ASP) TREND
5.11 PATENT ANALYSIS
FIGURE 20 GRANTED PATENTS FOR PDX MODELS, 2011–2023
5.12 KEY CONFERENCES AND EVENTS IN 2023
TABLE 8 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: KEY CONFERENCES AND EVENTS
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
5.13.2 BUYING CRITERIA
FIGURE 22 KEY BUYING CRITERIA FOR THREE KEY END USERS
6 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD
6.1 INTRODUCTION
TABLE 9 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
6.2 SUBCUTANEOUS IMPLANTATION
6.2.1 FACILITATES REAL-TIME ASSESSMENT OF TUMOR GROWTH
TABLE 10 SUBCUTANEOUS IMPLANTATION: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 11 SUBCUTANEOUS IMPLANTATION: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 12 SUBCUTANEOUS IMPLANTATION: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 13 SUBCUTANEOUS IMPLANTATION: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 14 SUBCUTANEOUS IMPLANTATION: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 15 SUBCUTANEOUS IMPLANTATION: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 ORTHOTOPIC IMPLANTATION
6.3.1 PROVIDES HIGHLY ACCURATE REPRESENTATION OF TUMOR BEHAVIOR
TABLE 16 ORTHOTOPIC IMPLANTATION: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 17 ORTHOTOPIC IMPLANTATION: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 18 ORTHOTOPIC IMPLANTATION: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 19 ORTHOTOPIC IMPLANTATION: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 20 ORTHOTOPIC IMPLANTATION: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 21 ORTHOTOPIC IMPLANTATION: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.4 OTHERS
TABLE 22 OTHERS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 23 OTHERS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 24 OTHERS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 25 OTHERS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 26 OTHERS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 27 OTHERS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE
7.1 INTRODUCTION
TABLE 28 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
7.2 MOUSE MODEL
7.2.1 GROWING USE IN CANCER RESEARCH AND DRUG DEVELOPMENT
TABLE 29 MOUSE MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 30 MOUSE MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 31 MOUSE MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 32 MOUSE MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 33 MOUSE MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 34 MOUSE MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 RAT MODEL
7.3.1 DEVELOPMENT OF NEW TECHNOLOGIES TO CREATE PDX RAT MODELS AT FASTER RATE
TABLE 35 RAT MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 36 RAT MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 37 RAT MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 38 RAT MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 39 RAT MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 40 RAT MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 41 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
8.2 PRECLINICAL DRUG DEVELOPMENT
8.2.1 INCREASED NUMBER OF CLINICAL TRIALS
TABLE 42 PRECLINICAL DRUG DEVELOPMENT: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 43 PRECLINICAL DRUG DEVELOPMENT: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 44 PRECLINICAL DRUG DEVELOPMENT: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 45 PRECLINICAL DRUG DEVELOPMENT: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 46 PRECLINICAL DRUG DEVELOPMENT: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 47 PRECLINICAL DRUG DEVELOPMENT: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 BIOMARKER ANALYSIS
8.3.1 GROWING DEMAND FOR BIOMARKER-BASED PERSONALIZED CANCER THERAPY
TABLE 48 BIOMARKER ANALYSIS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 49 BIOMARKER ANALYSIS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 50 BIOMARKER ANALYSIS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 51 BIOMARKER ANALYSIS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 52 BIOMARKER ANALYSIS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 53 BIOMARKER ANALYSIS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8.4 TRANSLATIONAL RESEARCH
8.4.1 BOOMING PERSONALIZED MEDICINE MARKET
TABLE 54 TRANSLATIONAL RESEARCH: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 55 TRANSLATIONAL RESEARCH: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 56 TRANSLATIONAL RESEARCH: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 57 TRANSLATIONAL RESEARCH: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 58 TRANSLATIONAL RESEARCH: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 59 TRANSLATIONAL RESEARCH: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8.5 BIOBANKS
8.5.1 RISING DRUG DISCOVERY AND DEVELOPMENT PROJECTS
TABLE 60 BIOBANKS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 61 BIOBANKS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 62 BIOBANKS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 63 BIOBANKS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 64 BIOBANKS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 65 BIOBANKS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
9 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER
9.1 INTRODUCTION
TABLE 66 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 ADVANCEMENTS IN TUMOR MICROENVIRONMENT RESEARCH
TABLE 67 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 68 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 69 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, 2021–2028 (USD MILLION)
TABLE 70 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 71 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 72 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
9.3 CONTRACT RESEARCH ORGANIZATIONS (CROS)
9.3.1 INCREASING OUTSOURCING OF DRUG DISCOVERY SERVICES
TABLE 73 CONTRACT RESEARCH ORGANIZATIONS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 74 CONTRACT RESEARCH ORGANIZATIONS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 75 CONTRACT RESEARCH ORGANIZATIONS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 76 CONTRACT RESEARCH ORGANIZATIONS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 77 CONTRACT RESEARCH ORGANIZATIONS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 78 CONTRACT RESEARCH ORGANIZATIONS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
9.4 ACADEMIC & RESEARCH INSTITUTIONS
9.4.1 RISING R&D INVESTMENTS IN LIFE SCIENCES
TABLE 79 ACADEMIC & RESEARCH INSTITUTIONS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 80 ACADEMIC & RESEARCH INSTITUTIONS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 81 ACADEMIC & RESEARCH INSTITUTIONS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 82 ACADEMIC & RESEARCH INSTITUTIONS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 83 ACADEMIC & RESEARCH INSTITUTIONS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 84 ACADEMIC & RESEARCH INSTITUTIONS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE
10.1 INTRODUCTION
TABLE 85 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
10.2 GASTROINTESTINAL TUMOR MODEL
10.2.1 RISING DEMAND FOR EFFECTIVE CANCER THERAPEUTICS
TABLE 86 GASTROINTESTINAL TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 87 GASTROINTESTINAL TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 88 GASTROINTESTINAL TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 89 GASTROINTESTINAL TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 90 GASTROINTESTINAL TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 91 GASTROINTESTINAL TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.3 GYNECOLOGICAL TUMOR MODEL
10.3.1 HIGH INCIDENCE OF TARGET CANCERS
TABLE 92 GYNECOLOGICAL TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 93 GYNECOLOGICAL TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 94 GYNECOLOGICAL TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 95 GYNECOLOGICAL TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 96 GYNECOLOGICAL TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 97 GYNECOLOGICAL TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.4 RESPIRATORY TUMOR MODEL
10.4.1 INCREASING PREVALENCE OF LUNG CANCER
TABLE 98 RESPIRATORY TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 99 RESPIRATORY TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 100 RESPIRATORY TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 101 RESPIRATORY TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 102 RESPIRATORY TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 103 RESPIRATORY TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.5 UROLOGICAL TUMOR MODEL
10.5.1 INCREASING FOCUS OF COMPANIES ON EXPANDING PORTFOLIO OF UROLOGICAL TUMOR MODELS
TABLE 104 UROLOGICAL TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 105 UROLOGICAL TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 106 UROLOGICAL TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 107 UROLOGICAL TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 108 UROLOGICAL TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 109 UROLOGICAL TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.6 HEMATOLOGICAL TUMOR MODEL
10.6.1 ADVANCEMENTS IN TRANSLATIONAL RESEARCH AND INCREASING DEMAND FOR PERSONALIZED MEDICINE
TABLE 110 HEMATOLOGICAL TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 111 HEMATOLOGICAL TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 112 HEMATOLOGICAL TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 113 HEMATOLOGICAL TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 114 HEMATOLOGICAL TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 115 HEMATOLOGICAL TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
10.7 OTHERS
TABLE 116 OTHERS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 117 OTHERS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 118 OTHERS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 119 OTHERS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 120 OTHERS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 121 OTHERS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
11 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION
11.1 INTRODUCTION
TABLE 122 PATIENT-DERIVED XENOGRAFT MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 23 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET SNAPSHOT
TABLE 123 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 124 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 125 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 126 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 127 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 128 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.1 US
11.2.1.1 Growing federal research and development efforts to drive market
TABLE 129 US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 130 US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 131 US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 132 US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 133 US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Government-led investments in stem cell research to drive market
TABLE 134 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 135 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 136 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 137 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 138 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.3 NORTH AMERICA: IMPACT OF RECESSION
11.3 EUROPE
TABLE 139 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 140 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 141 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 142 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 143 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 144 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Increasing investments in biotechnology industry to boost market growth
TABLE 145 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 146 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 147 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 148 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 149 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.2 FRANCE
11.3.2.1 Increasing government funding for cancer research to support market growth
TABLE 150 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 151 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 152 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 153 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 154 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.3 UK
11.3.3.1 Rising focus on innovating oncology therapeutics to drive market
TABLE 155 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 156 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 157 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 158 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 159 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Growing biotechnology and pharmaceutical industries to drive market
TABLE 160 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 161 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 162 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 163 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 164 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Increasing investments in clinical trials to promote market growth
TABLE 165 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 166 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 167 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 168 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 169 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.6 REST OF EUROPE
TABLE 170 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 171 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 172 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 173 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 174 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.7 EUROPE: IMPACT OF RECESSION
11.4 ASIA PACIFIC
FIGURE 24 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET SNAPSHOT
TABLE 175 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 176 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 177 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 178 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 179 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 180 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.1 CHINA
11.4.1.1 Government-led fundings for clinical trials in oncology to drive market
TABLE 181 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 182 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 183 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 184 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 185 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Advancements in mice model technologies to drive market
TABLE 186 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 187 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 188 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 189 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 190 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Favorable government policies for drug development to fuel demand
TABLE 191 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 192 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 193 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 194 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 195 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.4 SOUTH KOREA
11.4.4.1 Rising investments in preclinical drug development to drive demand
TABLE 196 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 197 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 198 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 199 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 200 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.5 AUSTRALIA
11.4.5.1 Increased funding in clinical trials from research institutions to drive market
TABLE 201 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 202 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 203 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 204 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 205 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.6 REST OF ASIA PACIFIC
TABLE 206 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 207 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 208 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 209 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 210 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.7 ASIA PACIFIC: IMPACT OF RECESSION
11.5 LATIN AMERICA
TABLE 211 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 212 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 213 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 214 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 215 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 216 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.1 BRAZIL
11.5.1.1 Growing need for advanced cancer research and therapeutic development to drive market
TABLE 217 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 218 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 219 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 220 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 221 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.2 REST OF LATIN AMERICA
TABLE 222 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 223 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 224 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 225 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 226 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.3 LATIN AMERICA: IMPACT OF RECESSION
11.6 MIDDLE EAST & AFRICA
TABLE 227 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 228 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 229 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 230 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 231 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 232 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.6.1 MIDDLE EAST
11.6.1.1 Growing use to probe treatment strategies aligned with individual patient profiles to drive market
TABLE 233 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 234 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 235 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 236 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 237 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.6.2 AFRICA
11.6.2.1 Rising incidence of cancer and expanding research infrastructure to drive market
TABLE 238 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 239 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
TABLE 240 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
TABLE 241 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 242 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
11.6.3 MIDDLE EAST & AFRICA: IMPACT OF RECESSION
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS
FIGURE 25 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: KEY STRATEGIES ADOPTED BY MAJOR PLAYERS
12.3 REVENUE SHARE ANALYSIS OF TOP FOUR PLAYERS, 2022
FIGURE 26 REVENUE SHARE ANALYSIS FOR TOP FOUR COMPANIES, 2022
12.4 MARKET SHARE ANALYSIS OF TOP FOUR PLAYERS, 2020–2022
FIGURE 27 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET SHARE ANALYSIS OF TOP FOUR PLAYERS, 2020–2022
12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 28 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
12.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMALL AND MEDIUM-SIZED ENTERPRISES (SMES), 2022
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
FIGURE 29 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022
12.7 COMPETITIVE BENCHMARKING
12.7.1 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: LIST OF STARTUPS/SMES
TABLE 243 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: LIST OF STARTUPS/SMES
12.7.2 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
TABLE 244 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
12.8 COMPETITIVE SCENARIOS AND TRENDS
12.8.1 DEALS
TABLE 245 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: DEALS, 2021–2023
12.8.2 OTHERS
TABLE 246 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: OTHERS, 2021–2023
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 JSR CORPORATION
TABLE 247 JSR CORPORATION: COMPANY OVERVIEW
FIGURE 30 JSR CORPORATION: COMPANY SNAPSHOT
13.1.2 WUXI APPTEC
TABLE 248 WUXI APPTEC: COMPANY OVERVIEW
FIGURE 31 WUXI APPTEC: COMPANY SNAPSHOT
13.1.3 THE JACKSON LABORATORY
TABLE 249 THE JACKSON LABORATORY: COMPANY OVERVIEW
FIGURE 32 THE JACKSON LABORATORY: COMPANY SNAPSHOT
13.1.4 CHARLES RIVER LABORATORIES
TABLE 250 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
FIGURE 33 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
13.1.5 TACONIC BIOSCIENCES, INC.
TABLE 251 TACONIC BIOSCIENCES, INC.: COMPANY OVERVIEW
13.1.6 ONCODESIGN PRECISION MEDICINE
TABLE 252 ONCODESIGN PRECISION MEDICINE: COMPANY OVERVIEW
FIGURE 34 ONCODESIGN PRECISION MEDICINE: COMPANY SNAPSHOT
13.1.7 INOTIV, INC.
TABLE 253 INOTIV, INC.: COMPANY OVERVIEW
FIGURE 35 INOTIV, INC.: COMPANY SNAPSHOT
13.1.8 PHARMATEST SERVICES
TABLE 254 PHARMATEST SERVICES: COMPANY OVERVIEW
13.1.9 HERA BIOLABS
TABLE 255 HERA BIOLABS: COMPANY OVERVIEW
13.1.10 EPO BERLIN-BUCH GMBH
TABLE 256 EPO BERLIN-BUCH GMBH: COMPANY OVERVIEW
13.1.11 XENTECH
TABLE 257 XENTECH: COMPANY OVERVIEW
13.1.12 UROSPHERE
TABLE 258 UROSPHERE: COMPANY OVERVIEW
13.1.13 ALTOGEN LABS
TABLE 259 ALTOGEN LABS: COMPANY OVERVIEW
13.1.14 ABNOVA CORPORATION
TABLE 260 ABNOVA CORPORATION: COMPANY OVERVIEW
13.1.15 GENESIS BIOTECHNOLOGY GROUP
TABLE 261 GENESIS BIOTECHNOLOGY GROUP: COMPANY OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS
13.2.1 BIOCYTOGEN PHARMACEUTICALS CO., LTD.
13.2.2 CREATIVE ANIMODEL
13.2.3 BIODURO-SUNDIA INC.
13.2.4 ARAGEN LIFE SCIENCES
13.2.5 SHANGHAI LIDE BIOTECH CO., LTD.
13.2.6 CERTIS ONCOLOGY SOLUTIONS
13.2.7 INNOSER
13.2.8 IVRS AB
13.2.9 BEIJING IDMO CO. LTD.
13.2.10 SHANGHAI CHEM PARTNER CO. LTD.
14 APPENDIX
14.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.2 CUSTOMIZATION OPTIONS
14.3 RELATED REPORTS
14.4 AUTHOR DETAILS
